Amantadine- and oseltamivir-resistant variants of influenza A viruses in Thailand

Biochemical and Biophysical Research Communications

Volumn 390, Issue 3, 2009, Pages 897-901

  Bai, Gui Rong ^a,b   Chittaganpitch, Malinee ^c   Kanai, Yuta ^a,b   Li, Yong Gang ^a,b   Auwanit, Wattana ^c   Ikuta, Kazuyoshi ^a,b   Sawanpanyalert, Pathom ^c  

^a Thailand Japan Research Collaboration Center on Emerging and Re emerging Infections RCC ERI   (Thailand)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Amantadine; Drug resistance; M2; Neuraminidase; Oseltamivir; Seasonal influenza

Indexed keywords

AMANTADINE; OSELTAMIVIR; PROTEIN M2; VIRUS SIALIDASE;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC REASSORTMENT; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; INFLUENZA; INFLUENZA VIRUS A; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; THAILAND; VIRAL GENETICS; VIRUS INFECTION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE;

AMANTADINE; ANTIVIRAL AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; GENES, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MUTATION; OSELTAMIVIR; PHYLOGENY; THAILAND;

INFLUENZA A VIRUS;

EID: 70449732106     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.10.071     Document Type: Article

References (35)

1. Nichol K.L. Complications of influenza and benefits of vaccination. Vaccine 17 Suppl. 1 (1999) S47-S52
2. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 17 Suppl. 1 (1999) S3-S10
3. Fleming D.M. Managing influenza: amantadine, rimantadine and beyond. Int. J. Clin. Pract. 55 (2001) 189-195
4. von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat. Rev. Drug Discov. 6 (2007) 967-974
5. Ziegler T., Hemphill M.L., Ziegler M.L., Perez-Oronoz G., Klimov A.I., Hampson A.W., Regnery H.L., and Cox N.J. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J. Infect. Dis. 180 (1999) 935-939
6. Deyde V.M., Xu X., Bright R.A., Shaw M., Smith C.B., Zhang Y., Shu Y., Gubareva L.V., Cox N.J., and Klimov A.I. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196 (2007) 249-257
7. McKimm-Breschkin J., Trivedi T., Hampson A., Hay A., Klimov A., Tashiro M., Hayden F., and Zambon M. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47 (2003) 2264-2272
8. Monto A.S., McKimm-Breschkin J.L., Macken C., Hampson A.W., Hay A., Klimov A., Tashiro M., Webster R.G., Aymard M., Hayden F.G., and Zambon M. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50 (2006) 2395-2402
9. Hurt A.C., and Barr I.G. Influenza viruses with reduced sensitivity to the neuraminidase inhibitor drugs in untreated young children. Commun. Dis. Intell. 32 (2008) 57-62
10. Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance, Wkly. Epidemiol. Rec. 80 (2005) 156.
11. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R.J., Xu X., Bright R.A., Butler E.N., Wallis T.R., Klimov A.I., and Gubareva L.V. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52 (2008) 3284-3292
12. WHO, Influenza A (H1N1) virus resistance to oseltamivir-2008 influenza season, southern hemisphere. Available from: (accessed October 2008).
13. Hurt A.C., Ernest J., Deng Y.M., Iannello P., Besselaar T.G., Birch C., Buchy P., Chittaganpitch M., Chiu S.C., Dwyer D., Guigon A., Harrower B., Kei I.P., Kok T., Lin C., McPhie K., Mohd A., Olveda R., Panayotou T., Rawlinson W., Scott L., Smith D., D'Souza H., Komadina N., Shaw R., Kelso A., and Barr I.G. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83 (2009) 90-93
14. Waicharoen S., Thawatsupha P., Chittaganpitch M., Maneewong P., Thanadachakul T., and Sawanpanyalert P. Influenza viruses circulating in Thailand in 2004 and 2005. Jpn. J. Infect. Dis. 61 (2008) 321-323
15. Barr I.G., Deng Y.M., Iannello P., Hurt A.C., and Komadina N. Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries. Antiviral Res. 80 (2008) 200-205
16. CDC, Control, Concepts and procedures for laboratory based influenza surveillance, Center for Disease Control, Atlanta, GA, 1982.
17. Hoffmann E., Stech J., Guan Y., Webster R.G., and Perez D.R. Universal primer set for the full-length amplification of all influenza A viruses. Arch. Virol. 146 (2001) 2275-2289
18. Tamura K., Dudley J., Nei M., and Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24 (2007) 1596-1599
19. Tang J.W., Ngai K.L., Wong J.C., Lam W.Y., and Chan P.K. Emergence of adamantane-resistant influenza A(H3N2) viruses in Hong Kong between 1997 and 2006. J. Med. Virol. 80 (2008) 895-901
20. Boivin G., Goyette N., and Bernatchez H. Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin. Infect. Dis. 34 (2002) 23-25
21. Hay A.J., Zambon M.C., Wolstenholme A.J., Skehel J.J., and Smith M.H. Molecular basis of resistance of influenza A viruses to amantadine. J. Antimicrob. Chemother. 18 Suppl. B (1986) 19-29
22. Lackenby A., Hungnes O., Dudman S.G., Meijer A., Paget W.J., Hay A.J., and Zambon M.C. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 13 (2008) 8026
23. Holmes E.C., Ghedin E., Miller N., Taylor J., Bao Y., St George K., Grenfell B.T., Salzberg S.L., Fraser C.M., Lipman D.J., and Taubenberger J.K. Whole-genome analysis of human influenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses. PLoS Biol. 3 (2005) e300
24. Saito R., Li D., Suzuki Y., Sato I., Masaki H., Nishimura H., Kawashima T., Shirahige Y., Shimomura C., Asoh N., Degawa S., Ishikawa H., Sato M., Shobugawa Y., and Suzuki H. High prevalence of amantadine-resistance influenza a (H3N2) in six prefectures, Japan, in the 2005-2006 season. J. Med. Virol. 79 (2007) 1569-1576
25. Barr I.G., Hurt A.C., Iannello P., Tomasov C., Deed N., and Komadina N. Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. Antiviral Res. 73 (2007) 112-117
26. Barr I.G., Hurt A.C., Deed N., Iannello P., Tomasov C., and Komadina N. The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006. Antiviral Res. 75 (2007) 173-176
27. Meijer A., Lackenby A., Hungnes O., Lina B., van-der-Werf S., Schweiger B., Opp M., Paget J., van-de-Kassteele J., Hay A., and Zambon M. Oseltamivir-resistant influenza virus A (H1N1), Europe, season 2007-08. Emerg. Infect. Dis. 15 (2009) 552-560
28. Russell C.A., Jones T.C., Barr I.G., Cox N.J., Garten R.J., Gregory V., Gust I.D., Hampson A.W., Hay A.J., Hurt A.C., de Jong J.C., Kelso A., Klimov A.I., Kageyama T., Komadina N., Lapedes A.S., Lin Y.P., Mosterin A., Obuchi M., Odagiri T., Osterhaus A.D., Rimmelzwaan G.F., Shaw M.W., Skepner E., Stohr K., Tashiro M., Fouchier R.A., and Smith D.J. The global circulation of seasonal influenza A (H3N2) viruses. Science 320 (2008) 340-346
29. Nelson M.I., Simonsen L., Viboud C., Miller M.A., and Holmes E.C. The origin and global emergence of adamantane resistant A/H3N2 influenza viruses. Virology 388 (2009) 270-278
30. CDC, Update: influenza activity-United States, September 28, 2008-April 4, 2009, and composition of the 2009-10 influenza vaccine, MMWR Morb. Mortal Wkly. Rep. 58 (2009) 369-374.
31. Simonsen L., Viboud C., Grenfell B.T., Dushoff J., Jennings L., Smit M., Macken C., Hata M., Gog J., Miller M.A., and Holmes E.C. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol. Biol. Evol. 24 (2007) 1811-1820
32. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., Povinelli L., Cox N.J., and Klimov A.I. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 (2005) 1175-1181
33. Saito R., Sakai T., Sato I., Sano Y., Oshitani H., Sato M., and Suzuki H. Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2. J. Clin. Microbiol. 41 (2003) 2164-2165
34. Masuda H., Suzuki H., Oshitani H., Saito R., Kawasaki S., Nishikawa M., and Satoh H. Incidence of amantadine-resistant influenza A viruses in sentinel surveillance sites and nursing homes in Niigata, Japan. Microbiol. Immunol. 44 (2000) 833-839
35. Bright R.A., Shay D.K., Shu B., Cox N.J., and Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295 (2006) 891-894